Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence. (Stedman, 25th ed)
Concept/Terms
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in Harvard Catalyst Profiles by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 8 | 0 | 8 |
| 1994 | 3 | 2 | 5 |
| 1995 | 4 | 4 | 8 |
| 1996 | 10 | 0 | 10 |
| 1997 | 6 | 2 | 8 |
| 1998 | 7 | 1 | 8 |
| 1999 | 3 | 0 | 3 |
| 2000 | 6 | 3 | 9 |
| 2001 | 8 | 1 | 9 |
| 2002 | 9 | 3 | 12 |
| 2003 | 18 | 2 | 20 |
| 2004 | 10 | 0 | 10 |
| 2005 | 6 | 3 | 9 |
| 2006 | 8 | 1 | 9 |
| 2007 | 7 | 0 | 7 |
| 2008 | 14 | 0 | 14 |
| 2009 | 9 | 3 | 12 |
| 2010 | 11 | 1 | 12 |
| 2011 | 10 | 0 | 10 |
| 2012 | 10 | 0 | 10 |
| 2013 | 22 | 2 | 24 |
| 2014 | 15 | 0 | 15 |
| 2015 | 17 | 3 | 20 |
| 2016 | 18 | 3 | 21 |
| 2017 | 20 | 2 | 22 |
| 2018 | 18 | 1 | 19 |
| 2019 | 24 | 2 | 26 |
| 2020 | 21 | 2 | 23 |
| 2021 | 25 | 0 | 25 |
| 2022 | 34 | 0 | 34 |
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis. Curr Oncol. 2022 Dec 20; 30(1):19-36.
-
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers. Expert Rev Mol Diagn. 2022 11; 22(11):997-1008.
-
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol. 2022 12; 23(12):1508-1516.
-
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nat Commun. 2022 11 02; 13(1):6575.
-
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2022 10 03; 28(19):4267-4277.
-
Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells. Biochem Biophys Res Commun. 2022 11 05; 628:76-83.
-
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight. 2022 08 22; 7(16).
-
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors. Target Oncol. 2022 09; 17(5):563-569.
-
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 08 15; 28(16):3452-3463.
-
Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy. Clin Genitourin Cancer. 2022 12; 20(6):543-552.